Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. | 1991 | Transplant. Proc. | pmid:1721253 | |
Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
Siekierka JJ et al. | Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. | 1991 | Transplant. Proc. | pmid:1721256 |
Farghali H et al. | FK 506 modulates D-galactosamine-induced hepatitis in rats. | 1991 | Transplant. Proc. | pmid:1721285 |
Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
Francavilla A et al. | The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. | 1991 | Transplant. Proc. | pmid:1721287 |
Jiang H et al. | Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. | 1991 | Transplant. Proc. | pmid:1721317 |
Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
Chen-Woan M et al. | Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721320 |
Morel P et al. | Liver retransplantation in adults: overall results and determinant factors affecting the outcome. | 1991 | Transplant. Proc. | pmid:1721349 |
Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
Schreiber SL | Chemistry and biology of the immunophilins and their immunosuppressive ligands. | 1991 | Science | pmid:1702904 |
Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
Green M et al. | Infectious complications of pediatric liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721352 |
Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
Kusne S et al. | Early infections in kidney transplant recipients under FK 506. | 1991 | Transplant. Proc. | pmid:1703364 |
Yamada K et al. | Short-term FK 506-induced morphological changes in rat kidneys. | 1991 | Transplant. Proc. | pmid:1721381 |
Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
Moutabarrik A et al. | In vitro FK 506 kidney tubular cell toxicity. | 1991 | Transplant. Proc. | pmid:1721383 |
Wang X et al. | Intraportal FK 506 improves intrahepatic islet allograft survival. | 1991 | Transplant. Proc. | pmid:1721412 |
Ohtsuka S et al. | The effect of short-term FK 506 therapy on pancreas transplantation in rats. | 1991 | Transplant. Proc. | pmid:1721413 |
Yamashita T et al. | Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. | 1991 | Transplant. Proc. | pmid:1721414 |
Fukuzaki T et al. | Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. | 1991 | Transplant. Proc. | pmid:1721415 |
Steinmann B et al. | Mechanism of action of FK 506 and cyclosporin. | 1991 | Lancet | pmid:1704088 |
Sewing KF and Christians U | FK 506. | 1991 | Lancet | pmid:1704090 |
Wiederrecht G et al. | FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1704127 |
Ziccardi VB et al. | Maxillofacial considerations in orthotopic liver transplantation. | 1991 | Oral Surg. Oral Med. Oral Pathol. | pmid:1704494 |
Wada H et al. | Dose response to FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721444 |
Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
Propper DJ et al. | Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. | 1991 | Transplant. Proc. | pmid:1721446 |
Fabrega AJ et al. | FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1721447 |
Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
Halloran PF and Madrenas J | The mechanism of action of cyclosporine: a perspective for the 90's. | 1991 | Clin. Biochem. | pmid:1711939 |
Palaszynski EW et al. | Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. | 1991 | Clin. Biochem. | pmid:1711940 |
Shiraki K et al. | Effect of FK-506 on replication of human cytomegalovirus in vitro. | 1991 | J. Antibiot. | pmid:1712008 |
Weaver JL et al. | Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. | 1991 | Immunopharmacol Immunotoxicol | pmid:1723084 |
DiLella AG and Craig RJ | Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. | 1991 | Biochemistry | pmid:1716149 |
Burres NS et al. | Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. | 1991 | J. Antibiot. | pmid:1723403 |
Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |
McKeon F | When worlds collide: immunosuppressants meet protein phosphatases. | 1991 | Cell | pmid:1716181 |
Petros AM et al. | NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. | 1991 | J. Med. Chem. | pmid:1716684 |
FK 506--an investigational immunosuppressant. | 1991 | Med Lett Drugs Ther | pmid:1716722 | |
Heitman J et al. | Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. | 1991 | Science | pmid:1715094 |
Morris RE | Rapamycin: FK506's fraternal twin or distant cousin? | 1991 | Immunol. Today | pmid:1715165 |
Baumann G et al. | Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. | 1991 | New Biol. | pmid:1715185 |
Liu J et al. | Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. | 1991 | Cell | pmid:1715244 |